CHARM Therapeutics closed an oversubscribed Series B funding round raising $80 million on September 2, 2025, to advance its AI-designed next-generation menin inhibitor for acute myeloid leukemia (AML) into clinical development in Q1 2026.12
The round was co-led by new investors NEA and SR One, with participation from existing investors OrbiMed, F-Prime, Khosla Ventures, and NVIDIA; total funding raised exceeds $150 million.12
The inhibitor, developed using proprietary DragonFold AI platform, overcomes resistance mutations seen in first-generation therapies, showing potency against all known clinical mutations and robust preclinical tumor regression.12
CHARM strengthened its board with appointments of Briggs Morrison, M.D. (former Syndax CEO) and Kim Blackwell, M.D. as non-executive directors.12
Sources:
1. https://charmtx.com/charm-therapeutics-raises-80-million-in-series-b-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-aml/
2. https://www.globenewswire.com/news-release/2025/09/02/3142466/0/en/CHARM-Therapeutics-raises-80-million-in-Series-B-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-AML.html